Enzymatica AB (SE:ENZY)
:ENZY
Want to see SE:ENZY full AI Analyst Report?
Top Page
Enzymatica AB
(ENZY)
Select Model
Select Model
Rating:49Neutral
Price Target:
kr2.50
▲(25.00% Upside)
Action:Reiterated
Date:05/27/26
The score is primarily held back by weak financial performance driven by persistent losses and significant cash burn, despite a low-debt balance sheet. Technicals provide some support as the stock trades above major moving averages, but valuation remains constrained by ongoing losses and the absence of dividend support.
Positive Factors
Conservative balance sheet / low leverage
Very low reported debt (debt-to-equity ~0.01) materially reduces refinancing and solvency risk. That conservatism provides enduring financial flexibility to absorb seasonal swings, preserve runway for commercialization, and pursue partnerships or investments without immediate capital restructuring pressure.
Negative Factors
Deep and persistent operating losses
TTM net margin near -96% and multi-year losses indicate entrenched profitability issues. Persistent operating losses erode shareholder value (ROE ~-37%) and limit internal funding for growth, meaning the company requires sustained margin improvement or external capital to achieve long-term viability.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low reported debt (debt-to-equity ~0.01) materially reduces refinancing and solvency risk. That conservatism provides enduring financial flexibility to absorb seasonal swings, preserve runway for commercialization, and pursue partnerships or investments without immediate capital restructuring pressure.
Read all positive factors
Enzymatica AB (ENZY) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr611.69M
Dividend YieldN/A
Average Volume (3M)93.66K
Price to Earnings (P/E)―
Beta (1Y)0.30
Revenue Growth9.56%
EPS Growth19.12%
CountrySE
Employees21
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.20
Shares Outstanding242,735,100
10 Day Avg. Volume44,136
30 Day Avg. Volume93,658
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)3.71
Price to Sales (P/S)8.56
P/FCF Ratio-11.19
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.3
Revenue Forecast (FY)kr109.00M
Enzymatica AB Business Overview & Revenue Model
Company Description
Enzymatica AB, a life science company headquartered in Lund, Sweden, focuses on the development and sale of medical devices for infection-related illnesses. Founded in 2007, its primary offering is the ColdZyme mouth spray, designed to help preven...
How the Company Makes Money
Enzymatica makes money primarily by selling its products (most notably ColdZyme) in consumer healthcare channels such as pharmacies, retail, and e-commerce. Revenue is generated through (1) direct sales in markets where Enzymatica operates its own...
Enzymatica AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 53.06M | 53.90M | 45.58M | 50.90M | 48.95M | 57.24M |
| Gross Profit | 31.10M | 33.13M | 30.72M | 31.86M | 28.45M | 33.35M |
| EBITDA | -48.04M | -46.81M | -49.23M | -41.12M | -59.97M | -38.19M |
| Net Income | -47.34M | -51.89M | -53.18M | -49.73M | -68.66M | -45.39M |
Balance Sheet | ||||||
| Total Assets | 128.07M | 141.98M | 195.22M | 125.91M | 174.41M | 157.04M |
| Cash, Cash Equivalents and Short-Term Investments | 26.06M | 33.13M | 75.21M | 8.37M | 50.69M | 31.62M |
| Total Debt | 661.00K | 1.02M | 2.20M | 18.08M | 22.32M | 2.60M |
| Total Liabilities | 17.18M | 17.81M | 18.86M | 49.30M | 48.12M | 32.07M |
| Stockholders Equity | 110.89M | 124.17M | 176.37M | 76.61M | 126.29M | 124.97M |
Cash Flow | ||||||
| Free Cash Flow | -27.76M | -41.20M | -60.90M | -41.02M | -68.28M | -42.00M |
| Operating Cash Flow | -39.19M | -40.97M | -60.51M | -40.29M | -64.57M | -35.87M |
| Investing Cash Flow | -305.00K | -231.00K | -393.00K | -730.00K | -3.72M | -6.13M |
| Financing Cash Flow | -1.06M | -789.00K | 127.65M | -1.39M | 87.37M | 49.53M |
Enzymatica AB Technical Analysis
Neutral
2.00
Price Trends
2.67
Negative
2.40
Positive
2.23
Positive
Market Momentum
-0.02
Positive
44.39
Neutral
19.98
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:ENZY, the sentiment is Neutral. The current price of 2 is below the 20-day moving average (MA) of 2.64, below the 50-day MA of 2.67, and below the 200-day MA of 2.23, indicating a neutral trend. The MACD of -0.02 indicates Positive momentum. The RSI at 44.39 is Neutral, neither overbought nor oversold. The STOCH value of 19.98 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for SE:ENZY.
Enzymatica AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | kr733.35M | -2.98 | ― | ― | -58.93% | -16.61% | |
52 Neutral | kr519.87M | -7.32 | -90.66% | ― | ― | -32.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | kr643.53M | -40.98 | -48.65% | ― | 79.13% | 55.77% | |
49 Neutral | kr611.69M | -12.92 | ― | ― | 9.56% | 19.12% | |
43 Neutral | kr195.06M | -4.24 | -530.21% | ― | -99.01% | -1.33% | |
43 Neutral | kr24.99M | -0.38 | ― | ― | -86.56% | 8.75% |
* Healthcare Sector Average
SE:ENZY
Enzymatica AB
2.52
-0.33
-11.58%
SE:ORX
Orexo AB
21.00
1.92
10.06%
SE:ALZCUR
AlzeCure Pharma AB
3.77
1.27
51.04%
SE:KLAR
Klaria Pharma Holding AB
0.79
0.37
86.15%
SE:NANEXA
Nanexa AB
3.91
1.66
73.39%
SE:ERMA
Enorama Pharma AB
0.34
-2.15
-86.49%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.